Hepatitis B virus and intrahepatic cholangiocarcinoma

Cancer Investigation

Volumn 25, Issue 1, 2007, Pages 55-58

  Gatselis, Nikolaos K ^a   Tepetes, Konstantinos ^a   Loukopoulos, Argirios ^a   Vasiou, Katerina ^a   Zafiriou, Athanasios ^a   Gioti, Chrisoula ^a   Dalekos, Georgios N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Cholangiocarcinoma; Cirrhosis; HBV; HCV

Indexed keywords

ADULT; ARTICLE; BILE DUCT CARCINOMA; BLOOD EXAMINATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; INTRAHEPATIC CHOLANGIOCARCINOMA; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TELANGIECTASIA; TUMOR LOCALIZATION; VIRUS GENE; VIRUS VIRULENCE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HEPATITIS B; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947247622     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601130722     Document Type: Article

References (24)

1. de Groen, P.C.; Gores, G.J.; LaRusso, N.F.; Gunderson, L.L.; Nagorney, D.M. Biliary tract cancers. N. Engl. J. Med. 1999, 341 (18), 1368-1378.
2. Colombari, R.; Tsui, W.M. Biliary tumors of the liver. Semin. Liver Dis. 1995, 15 (4), 402-413.
3. Altaee, M.Y.; Johnson, P.J.; Farrant, J.M.; Williams, R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991, 68 (9), 2051-2055.
4. Colombo, M.; Sangiovanni, A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 2003, 60 (2), 145-150.
5. Tomimatsu, M.; Ishiguro, N.; Taniai, M.; Okuda, H.; Saito, A.; Obata, H.; Yamamoto, M.; Takasaki, K.; Nakano, M. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993, 72 (3), 683-688.
6. Parkin, D.M.; Srivatanakul, P.; Khlat, M.; Chenvidhya, D.; Chotiwan, P.; Insiripong, S.; L'Abbe, K.A.; Wild, C.P. Liver cancer in Thailand. I. a case-control study of cholangiocarcinoma. Int. J. Cancer 1991, 48 (3), 323-328.
7. Yamamoto, M.; Takasaki, K.; Nakano, M.; Saito, A. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998, 82 (11), 2145-2149.
8. Songsivilai, S.; Dharakul, T.; Kanistanon, D. Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand. Trans. R Soc. Trop. Med. Hyg. 1996, 90 (5), 505-507.
9. Kobayashi, M.; Ikeda, K.; Saitoh, S.; et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000, 88 (11), 2471-2477.
10. Sorensen, H.T.; Friis, S.; Olsen, J.H.; et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998, 28 (4), 921-925.
11. Shin, H.R.; Lee, C.U.; Park, H.J.; et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int. J. Epidemiol. 1996, 25 (5), 933-940.
12. Polizos, A.; Kelekis, N.; Sinani, C.; et al. Advanced intrahepatic cholangiocarcinoma in hepatitis C virus related decompensated cirrhosis: Case report and review of the literature. Eur. J. Gastroenterol. Hepatol. 2003, 15 (3), 331-334.
13. Kim, C.M.; Koike, K.; Saito, I.; Miyamura, T.; Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351 (6324), 317-320.
14. Wang, W.L.; Gu, G.Y.; Hu, M. Expression and significance of HBV genes and their antigens in human primary intrahepatic cholangiocarcinoma. World J. Gastroenterol. 1998, 4 (5), 392-396.
15. Liu, X.F.; Zou, S.Q.; Qiu, F.Z. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat. Dis. Int. 2003, 2 (2), 285-289.
16. Khan, S.A; Davidson, B.R; Goldin, R; et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002, 51 (Suppl. VI), 1-9.
17. Gores, G.J. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000, 6 (Suppl. 2), 30-34.
18. Patel, A.H.; Harnois, D.M.; Klee, G.G.; LaRusso, N.F.; Gores, G.J. The utility of CA 19-9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 2000, 95, 204-207.
19. Bruix, J.; Sherman, M.; Llovet, J.M.; et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J. Hepatol. 2001, 35, 421-430.
20. Danta, M.; Barnes, E.; Dusheiko, G. The surveillance and diagnosis of hepatocellular carcinoma. Eu.r J. Gastroenterol. Hepatol. 2005, 17, 491-496.
21. Natoli, G.; Avantaggiati, M.L.; Chirillo, P.; et al. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol. Cell Biol. 1994, 14 (2), 989-998.
22. Wang, X.W.; Gibson, M.K.; Vermeulen, W.; et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995, 55 (24), 6012-6016.
23. Wang, X.W.; Forrester, K.; Yeh, H.; et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 1994, 91 (6), 2230-2234.
24. Vyberg, M. The hepatitis-associated bile duct lesion. Liver 1993, 13 (6), 289-301.